These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 35403793)

  • 1. Efficacy and safety of cotadutide, a dual glucagon-like peptide-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease.
    Parker VER; Hoang T; Schlichthaar H; Gibb FW; Wenzel B; Posch MG; Rose L; Chang YT; Petrone M; Hansen L; Ambery P; Jermutus L; Heerspink HJL; McCrimmon RJ
    Diabetes Obes Metab; 2022 Jul; 24(7):1360-1369. PubMed ID: 35403793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, safety, tolerability and efficacy of cotadutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, in phase 1 and 2 trials in overweight or obese participants of Asian descent with or without type 2 diabetes.
    Asano M; Sekikawa A; Kim H; Gasser RA; Robertson D; Petrone M; Jermutus L; Ambery P
    Diabetes Obes Metab; 2021 Aug; 23(8):1859-1867. PubMed ID: 33908687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon Agonist.
    Parker VER; Robertson D; Wang T; Hornigold DC; Petrone M; Cooper AT; Posch MG; Heise T; Plum-Moerschel L; Schlichthaar H; Klaus B; Ambery PD; Meier JJ; Hirshberg B
    J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31608926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
    Ambery P; Parker VE; Stumvoll M; Posch MG; Heise T; Plum-Moerschel L; Tsai LF; Robertson D; Jain M; Petrone M; Rondinone C; Hirshberg B; Jermutus L
    Lancet; 2018 Jun; 391(10140):2607-2618. PubMed ID: 29945727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety/tolerability, efficacy and pharmacokinetics of 600-μg cotadutide in Japanese type 2 diabetes patients with a body mass index of 25 kg/m
    Asano M; Sekikawa A; Sugeno M; Matsuoka O; Robertson D; Hansen L
    Diabetes Obes Metab; 2023 Aug; 25(8):2290-2299. PubMed ID: 37337366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual glucagon-like peptide-1 and glucagon receptor agonism reduces energy intake in type 2 diabetes with obesity.
    Golubic R; Kennet J; Parker V; Robertson D; Luo D; Hansen L; Jermutus L; Ambery P; Ryaboshapkina M; Surakala M; Laker RC; Venables M; Koulman A; Park A; Evans M
    Diabetes Obes Metab; 2024 Jul; 26(7):2634-2644. PubMed ID: 38562018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study.
    Nahra R; Wang T; Gadde KM; Oscarsson J; Stumvoll M; Jermutus L; Hirshberg B; Ambery P
    Diabetes Care; 2021 Jun; 44(6):1433-1442. PubMed ID: 34016612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and Safety of Cotadutide, a GLP-1 and Glucagon Receptor Dual Agonist, in Individuals with Renal Impairment: A Single-Dose, Phase I, Bridging Study.
    Klein G; Petrone M; Yang Y; Hoang T; Hazlett S; Hansen L; Flor A
    Clin Pharmacokinet; 2023 Jun; 62(6):881-890. PubMed ID: 37140727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
    Heise T; Mari A; DeVries JH; Urva S; Li J; Pratt EJ; Coskun T; Thomas MK; Mather KJ; Haupt A; Milicevic Z
    Lancet Diabetes Endocrinol; 2022 Jun; 10(6):418-429. PubMed ID: 35468322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
    Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease.
    Selvarajah V; Robertson D; Hansen L; Jermutus L; Smith K; Coggi A; Sánchez J; Chang YT; Yu H; Parkinson J; Khan A; Chung HS; Hess S; Dumas R; Duck T; Jolly S; Elliott TG; Baker J; Lecube A; Derwahl KM; Scott R; Morales C; Peters C; Goldenberg R; Parker VER; Heerspink HJL;
    Kidney Int; 2024 Dec; 106(6):1170-1180. PubMed ID: 39218393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterisation of cotadutide's dual GLP-1/glucagon receptor agonistic effects on glycaemic control using an in vivo human glucose regulation quantitative systems pharmacology model.
    Bosch R; Petrone M; Arends R; Vicini P; Sijbrands EJG; Hoefman S; Snelder N
    Br J Pharmacol; 2024 Jun; 181(12):1874-1885. PubMed ID: 38403793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.
    Mosenzon O; Blicher TM; Rosenlund S; Eriksson JW; Heller S; Hels OH; Pratley R; Sathyapalan T; Desouza C;
    Lancet Diabetes Endocrinol; 2019 Jul; 7(7):515-527. PubMed ID: 31189517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes.
    Jiang H; Pang S; Zhang Y; Yu T; Liu M; Deng H; Li L; Feng L; Song B; Han-Zhang H; Ma Q; Qian L; Yang W
    Nat Commun; 2022 Jun; 13(1):3613. PubMed ID: 35750681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease.
    Mann JFE; Fonseca VA; Poulter NR; Raz I; Idorn T; Rasmussen S; von Scholten BJ; Mosenzon O;
    Clin J Am Soc Nephrol; 2020 Apr; 15(4):465-473. PubMed ID: 32132141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population Pharmacokinetic Modeling of Cotadutide: A Dual Agonist Peptide of Glucagon-Like Peptide and Glucagon Receptors Administered to Participants with Type II Diabetes Mellitus, Chronic Kidney Disease, Obesity and Non-Alcoholic Steatohepatitis.
    Yu H; Åstrand M; Cheng J; Nitin K; Hamrén B; Khan AA
    Clin Pharmacokinet; 2024 Feb; 63(2):255-267. PubMed ID: 38236561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cotadutide promotes glycogenolysis in people with overweight or obesity diagnosed with type 2 diabetes.
    Parker VER; Robertson D; Erazo-Tapia E; Havekes B; Phielix E; de Ligt M; Roumans KHM; Mevenkamp J; Sjoberg F; Schrauwen-Hinderling VB; Johansson E; Chang YT; Esterline R; Smith K; Wilkinson DJ; Hansen L; Johansson L; Ambery P; Jermutus L; Schrauwen P
    Nat Metab; 2023 Dec; 5(12):2086-2093. PubMed ID: 38066113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin: The GetGoal-L-C randomized trial.
    Yang W; Min K; Zhou Z; Li L; Xu X; Zhu D; Venkateshwar Rao A; Murthy LS; Zhang N; Li I; Niemoeller E; Shang S
    Diabetes Obes Metab; 2018 Feb; 20(2):335-343. PubMed ID: 28742225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia).
    Yu Pan C; Han P; Liu X; Yan S; Feng P; Zhou Z; Lv X; Tian H; Jin Kui Y; Su B; Shang S; Niemoeller E
    Diabetes Metab Res Rev; 2014 Nov; 30(8):726-35. PubMed ID: 24639432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.